Pharma BD Deal Intelligence
Boston Scientific's $4.2 billion cash acquisition of BTG plc widened its interventional medicine footprint, adding TheraSphere in interventional oncology alongside the EKOS endovascular system and Varithena—a bolt-on that strengthened an existing therapeutic adjacency rather than a transformative bet.
Boston Scientific makes $4.2B offer to buy BTG and build out its oncology and vascular franchises with minimally invasive cancer and vascular treatments.
Boston Scientific closes acquisition of BTG plc on August 20 2019 completing its second largest acquisition ever after the $26B Guidant purchase.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Boston Scientific acquired BTG plc for approximately $4.2 billion in cash. The acquisition expanded Boston Scientific's interventional medicine portfolio, particularly in interventional oncology and vascular therapies.
200K US cases/yr · $5.0B Global peripheral vascular intervention devices
Peripheral vascular disease encompasses conditions affecting blood vessels outside the heart and brain. PAD is most common. Endovascular interventions have become first-line for many patients.
Medical: antiplatelet, statins, exercise. Endovascular: angioplasty, stenting, atherectomy. EKOS system for PE/DVT. Key device players: Boston Scientific, Medtronic, Abbott, Cook Medical.
150K US cases/yr · $4.0B Global interventional oncology devices
Interventional oncology uses image-guided minimally invasive procedures to treat tumors. Includes radioembolization (Y90/TheraSphere), ablation, and embolization for liver, lung, and kidney tumors.
Boston Scientific (TheraSphere), Sirtex/Varian (SIR-Spheres), Medtronic (ablation), AngioDynamics (NanoKnife). Growing adoption in liver-directed therapy.
Boston Scientific completed $4.2B acquisition of BTG plc, expanding interventional medicine portfolio with vascular and oncology products including TheraSphere.
BTG portfolio fully integrated into Boston Scientific's Peripheral Interventions division, adding revenue-generating products across interventional radiology.
BTG strengthened BSX's interventional medicine franchise with immediately revenue-generating products. TheraSphere and Varithena provided complementary growth.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boston Scientific Corporation / BTG plc (this deal) | 2018 | $4.2B | 78 |
| Boston Scientific Corporation / Endo International plc (American Medical Systems Men's Health and Prostate Health) | 2015 | $1.6B | 82 |
| Boston Scientific Corporation / Advanced Bionics Corporation | 2004 | $740M | 26 |
| Boston Scientific Corporation / Bolt Medical, Inc. | 2025 | — | — |
| Boston Scientific Corporation / Vertiflex, Inc. | 2019 | $465M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2018 deals · Boston Scientific Corporation deals · Oncology deals